Montelukast Krka

Montelukast, the active ingredient in Montelukast Krka, is a leukotriene receptor antagonist presented as a tablet for oral use. It is employed in the maintenance treatment of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in patients requiring long‑term control. GNH USA supplies Montelukast Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on leukotriene pathways to manage chronic respiratory and allergic conditions. - Asthma: provides maintenance therapy to reduce frequency of bronchospasm and improve lung function. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal or perennial allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity in susceptible individuals.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Upper respiratory tract infection: transient symptoms. - Abdominal pain: occasional discomfort. - Cough: non‑productive. - Diarrhoea: self‑limiting. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Mood changes: including depression or suicidal thoughts. - Angioedema: swelling of face, lips or tongue. - Hepatotoxicity: elevated liver enzymes. - Severe allergic reaction: anaphylaxis. - Stevens‑Johnson syndrome: severe skin eruption.

Before prescribing Montelukast, consider patient‑specific factors and monitoring needs. - Pregnancy: safety not established; weigh potential benefits against risks. - Breastfeeding: unknown excretion; assess necessity. - Hepatic impairment: use with caution; monitor liver function. - Psychiatric disorders: monitor for mood changes or suicidal ideation. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Phenobarbital or rifampicin: may reduce montelukast plasma concentrations. - Strong CYP3A4 inhibitors (e.g., ketoconazole): potential increase in exposure, monitor for adverse effects.

Moderate Interactions (Monitor Closely): - Warfarin: occasional reports of altered INR; check coagulation status. - Beta‑agonists: additive bronchodilatory effect, may enhance symptom control. - Antidepressants: monitor for mood changes when combined with montelukast.